The iMAM workflow was split into two separate sub studies consisting of independent discovery and monitoring phases for each. The first study consisted of analysis via SEC while the second study was via SCX with pH gradient elution. Like the convenNonal MAM workflow, the DS reference material was analysed during the discovery phase (Phase I) of the workflow to idenNfy the CQAs to be targeted during the iMAM monitoring phase (Phase II), Table . N-glycosylation was observed via both SCX and SEC analysis, peptide clipping was idenNfied in SCX analysis and dimer formation was only detected in SEC analysis. A separate intact workbook was created for both the SEC and SCX studies during the discovery phase. These intact workbooks were imported into Chromeleon CDS to create the iMAM processing methods for the monitoring phase of the workflows. For both the SEC and SCX studies, the four commercial DP batches were analysed. The 5 most abundant glycoforms on the Fc region were investigated independently via SCX and SEC chromatography coupled to MS. The core fucosylated agalactosyl biantennary glycan pair, A2G0F_A2G0F, was observed to be the most abundant pair present in both studies. The pair were observed at consistent levels for the four DP batches and DS ranging from 67.76% to 70.51% for the SEC study and 71.44% to 72.05% for the SCX results. The next most abundant proteoform was the A2G0F_A2G1F variant for both the SCX and SEC studies. The pair were observed at consistent levels for the four DP batches and DS ranging from 15.70% to 16.02% for SCX and 15.86% to 17.06% for SEC analysis. The A2G1F_A2G1F proteoform for both studies was the third must abundant pair observed, with consistent levels observed for the four DP batches and DS ranging from 6.24% to 6.83% for SCX and 6.70% to 6.93% for SEC.